Update on azole antifungals

Dimitrios I. Zonios, John E. Bennett

Research output: Contribution to journalArticle

Abstract

This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use. Key clinical trials are briefly discussed, and specific drug indications summarized. Fluconazole remains a valuable low-cost choice for the treatment of various fungal infections, including candidiasis and cryptococcosis. It has relatively few drug interactions and is safe but lacks activity against filamentous fungi. The use of itraconazole is historically plagued by erratic bioavailability of the oral capsule, improved with the oral solution. Drug interactions are numerous. Itraconazole exhibits significant activity against Aspergillus and the endemic fungi. Voriconazole has revolutionized the treatment of aspergillosis in severely immunocompromised patients, but its use is compromised by complicated pharmacokinetics, notable drug interactions, and relatively significant adverse events. Finally, posaconazole is the last addition to the azole armamentarium with extended antifungal spectrum, significant activity against the zygomycetes, and, apparently, optimal safety profile. Posaconazole has a significant role for the prophylaxis of invasive fungal infections in severely immunocompromised patients. Multiple daily dosing, a need for fatty foods for absorption, and absence of an intravenous formulation restrict its use to selected populations.

Original languageEnglish (US)
Pages (from-to)198-210
Number of pages13
JournalSeminars in Respiratory and Critical Care Medicine
Volume29
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Azoles
Drug Interactions
Itraconazole
Fluconazole
Immunocompromised Host
Fungi
Cryptococcosis
Triazoles
Aspergillosis
Mycoses
Candidiasis
Aspergillus
Health Care Costs
Biological Availability
Capsules
Pharmacokinetics
Clinical Trials
Pharmacology
Safety
Food

Keywords

  • Azole interactions
  • Azoles
  • Fluconazole
  • Itraconazole
  • Posaconazole
  • Triazoles
  • Voriconazole

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Critical Care

Cite this

Update on azole antifungals. / Zonios, Dimitrios I.; Bennett, John E.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 29, No. 2, 04.2008, p. 198-210.

Research output: Contribution to journalArticle

Zonios, Dimitrios I. ; Bennett, John E. / Update on azole antifungals. In: Seminars in Respiratory and Critical Care Medicine. 2008 ; Vol. 29, No. 2. pp. 198-210.
@article{45011e475bba40888fe9fefc81325851,
title = "Update on azole antifungals",
abstract = "This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use. Key clinical trials are briefly discussed, and specific drug indications summarized. Fluconazole remains a valuable low-cost choice for the treatment of various fungal infections, including candidiasis and cryptococcosis. It has relatively few drug interactions and is safe but lacks activity against filamentous fungi. The use of itraconazole is historically plagued by erratic bioavailability of the oral capsule, improved with the oral solution. Drug interactions are numerous. Itraconazole exhibits significant activity against Aspergillus and the endemic fungi. Voriconazole has revolutionized the treatment of aspergillosis in severely immunocompromised patients, but its use is compromised by complicated pharmacokinetics, notable drug interactions, and relatively significant adverse events. Finally, posaconazole is the last addition to the azole armamentarium with extended antifungal spectrum, significant activity against the zygomycetes, and, apparently, optimal safety profile. Posaconazole has a significant role for the prophylaxis of invasive fungal infections in severely immunocompromised patients. Multiple daily dosing, a need for fatty foods for absorption, and absence of an intravenous formulation restrict its use to selected populations.",
keywords = "Azole interactions, Azoles, Fluconazole, Itraconazole, Posaconazole, Triazoles, Voriconazole",
author = "Zonios, {Dimitrios I.} and Bennett, {John E.}",
year = "2008",
month = "4",
doi = "10.1055/s-2008-1063858",
language = "English (US)",
volume = "29",
pages = "198--210",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Update on azole antifungals

AU - Zonios, Dimitrios I.

AU - Bennett, John E.

PY - 2008/4

Y1 - 2008/4

N2 - This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use. Key clinical trials are briefly discussed, and specific drug indications summarized. Fluconazole remains a valuable low-cost choice for the treatment of various fungal infections, including candidiasis and cryptococcosis. It has relatively few drug interactions and is safe but lacks activity against filamentous fungi. The use of itraconazole is historically plagued by erratic bioavailability of the oral capsule, improved with the oral solution. Drug interactions are numerous. Itraconazole exhibits significant activity against Aspergillus and the endemic fungi. Voriconazole has revolutionized the treatment of aspergillosis in severely immunocompromised patients, but its use is compromised by complicated pharmacokinetics, notable drug interactions, and relatively significant adverse events. Finally, posaconazole is the last addition to the azole armamentarium with extended antifungal spectrum, significant activity against the zygomycetes, and, apparently, optimal safety profile. Posaconazole has a significant role for the prophylaxis of invasive fungal infections in severely immunocompromised patients. Multiple daily dosing, a need for fatty foods for absorption, and absence of an intravenous formulation restrict its use to selected populations.

AB - This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use. Key clinical trials are briefly discussed, and specific drug indications summarized. Fluconazole remains a valuable low-cost choice for the treatment of various fungal infections, including candidiasis and cryptococcosis. It has relatively few drug interactions and is safe but lacks activity against filamentous fungi. The use of itraconazole is historically plagued by erratic bioavailability of the oral capsule, improved with the oral solution. Drug interactions are numerous. Itraconazole exhibits significant activity against Aspergillus and the endemic fungi. Voriconazole has revolutionized the treatment of aspergillosis in severely immunocompromised patients, but its use is compromised by complicated pharmacokinetics, notable drug interactions, and relatively significant adverse events. Finally, posaconazole is the last addition to the azole armamentarium with extended antifungal spectrum, significant activity against the zygomycetes, and, apparently, optimal safety profile. Posaconazole has a significant role for the prophylaxis of invasive fungal infections in severely immunocompromised patients. Multiple daily dosing, a need for fatty foods for absorption, and absence of an intravenous formulation restrict its use to selected populations.

KW - Azole interactions

KW - Azoles

KW - Fluconazole

KW - Itraconazole

KW - Posaconazole

KW - Triazoles

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=41149098251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149098251&partnerID=8YFLogxK

U2 - 10.1055/s-2008-1063858

DO - 10.1055/s-2008-1063858

M3 - Article

C2 - 18366001

AN - SCOPUS:41149098251

VL - 29

SP - 198

EP - 210

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 2

ER -